Analyst Upgrades

• Akamai (AKAM) to overweight from neutral at Piper Jaffray.
• Las Vegas Sands (LVS) to buy from neutral at UBS.
• Aetna (AET) to Outperform from market perform at Leerink.
• Hot Topic (HOTT) to buy from neutral at Janney Capital.
• Colonial Properties (CLP) upgraded to Outperform from market perform at FBR Capital and to buy from hold at Citigroup.
• Altera (ALTR) to buy from hold at Citigroup.
• American Reprographics (ARC), CarMax (KMX) and American Campus (ACC) to outperform from neutral at RW Baird.
• Zebra Tech (ZBRA) to neutral from underweight at JPMorgan.
• IMAX (IMAX) to buy from hold at Canaccord.
• Basic Energy (BAS) to neutral from sell at Goldman.
• Mednax (MD) to buy from neutral at BofA/Merrill.
• UTi Worldwide (UTIW) to buy from hold at Stifel Nicolaus.

Our recommendations center on a collection of five stocks that we believe, as a group, will outperform the market this month. The Buyback Premium Portfolio is beating the S&P 500 by more than 65% since its inception (August 2, 2000)! This portfolio is up 54.48% since inception (August 2, 2000) vs. a decline of 10.56% in the S&P 500 over the same time frame. We hope that you are participating in these profits. For the month of January 2011, The Buyback Premium Portfolio gained 1.18% vs. a gain of 2.27% in the S&P 500.

Analyst Upgrades

• Aetna (AET) to buy from neutral at Goldman.
• Kellogg (K) to buy from neutral at UBS.
• PetSmart (PETM) to outperform from market perform at JMP Securities.
• NetApp (NTAP) and Scripps Networks (SNI) to buy from hold at Wunderlich.
• Thoratec (THOR) to buy from hold at Auriga.
• ArcelorMittal (MT) to overweight from neutral at HSBC.
• Bristol-Myers (BMY) to outperform from neutral at Cowen.
• Eaton Vance (EV) to neutral from sell at Ticonderoga.
• Adtran (ADTN) to buy from underperform at BofA/Merrill.

Over the next couple decades, the healthcare industry will undergo major disruptive changes. Part of this will be the result of Obama care. And of course, a key factor will be the onslaught of the Baby Boomers, as they reach the retirement zone.

To deal with the costs and the complexities, the federal government is pushing hard for medical records. It seems like no-brainer, right?

Well, the major health insurers are certainly waking up. For example, this week Aetna (AET) agreed to shell out a cool $500 million for Medicity.

Analyst Upgrades

• Deutsche Bank upgraded Illinois Tool Works (ITW) to buy from hold, citing valuation and the company's strong revenue performance. The firm has a $60 price target for shares.
• Goldman upgraded PPD Inc. (PPDI) to buy from hold and raised its price target to $31 from $28. The firm expects strong top line growth and bookings momentum for the upgrade.
• Stifel Nicolaus upgraded Insituform Technologies (INSU) to buy from hold based on higher estimates for sewer rehab and energy. The firm has a $31 target on the stock.
• Patterson-UTI Energy (PTEN) was upgraded to overweight from equal weight at Morgan Stanley.
• Wisconsin Energy (WEC) and Northeast Utilities (NU) were upgraded to buy from neutral at UBS.
• Rockwell Collins (COL) was upgraded to buy from neutral at BofA/Merrill.

Analyst Upgrades

• Janney Montgomery upgraded Microsoft (MSFT) to buy from neutral with a $30 price target, citing valuation and expectations for strong Q4 results.
• UBS upgraded SanDisk (SNDK) to buy from neutral based on favorable pricing and mobile design win momentum. The firm raised its target to $55 from $46.
• BMO Capital upgraded Medtronic (MDT) to outperform from market perform based on valuation and its product pipeline. The firm has a $48 price target on the stock.
• Lorillard (LO) and Qualcomm (QCOM) were upgraded to conviction buy from buy at Goldman.
• Monsanto (MON) was upgraded to buy from hold at Citigroup.
• FedEx (FDX) was upgraded to buy from hold at BB&T.

Pending home sales rose 21.1% in March over 2009 numbers. The big driver was the expiration of the first time home buyer credit. Contracts had to be signed by the end of March to qualify. Nevertheless, these numbers are encouraging.

The National Association of Realtors' (NAT)' index stood at 102.9, up 5.3% It should be noted that pending sales lead existing sales by one to two months.

Separately, the Commerce Department released their numbers on manufactured goods. Excluding defense, factory orders were up 1.3%. Non defense capital goods, excluding aircraft were up 4.5%

Humana Inc. (HUM), whose colleagues include Aetna Inc. (AET) and CIGNA Corporation (CI), reported Q1 earnings earlier today. The health insurer isn't doing so well, unfortunately. In late trading, shares were down almost 3% to $43.73. Volume is above the norm, as you might expect.

I've covered many stocks that are near their 52-week highs, but this one doesn't fall into such a desirable category. Alas, the 52-week high on the shares stands at $52.66. And, as you can see from the following one-year chart, the stock began its pullback after it topped out in January. Since then, things haven't been too exciting.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Aetna Inc. (AET) shares declined after the insurer issued a surprise earnings warning for 2010.
• Alcoa Inc. (AA) swung to a smaller-than-expected Q4 profit even as revenue declined, sending shares lower.
• Carter's Inc. (CRI) posted strong Q3 earnings that topped estimates and same-store sales growth.
• Chevron Corp. (CVX) shares declined slightly after the company issued a surprise earnings warning.
• Con-Way Inc. (CNW) was downgraded due in part to concerns about near-term earnings.

Back in August, I discussed my amazement at Abercrombie & Fitch (ANF). The stock just didn't seem to be acting in a manner which reflected the fundamentals of the business it represents. Well, my bout of amazement continues, because shares of the retailer are up 9% as of this writing on the latest earnings report. One that didn't impress me.

For the third quarter, Abercrombie made, on a reported basis, 44 cents per diluted share compared to 72 cents per diluted share in the year-ago period. After adjustments, earnings came in at 30 cents per share. Okay, that profit drop is bad enough, but wait till I get to the really bad stuff. Which would be revenues. Total sales declined 15%, but same-store sales were even worse: they plunged off the proverbial cliff, falling 22%.